https://techpapersworld.com/wp-content/uploads/2022/12/Reaction-Biology-Acquires-Bioassay-GmbH-1280x720.jpg

Reaction Biology Corporation (“Reaction”), an industry-leading provider of drug discovery and development services, today announced that the Company has closed on a definitive agreement for Reaction to acquire Bioassay Labor für biologische Analytik GmbH (“Bioassay”), including its wholly-owned subsidiary, Peptide Specialty Laboratories GmbH (“PSL”), located in Heidelberg, Germany. Bioassay offers Good Manufacturing Practices (GMP) accredited potency assays and functional bioassays, Good Laboratory Practices (GLP) compliant services, and through PSL, peptide synthesis services, including peptide-specific antibody production and...

https://techpapersworld.com/wp-content/uploads/2022/11/Renaissance-BioScience-Corp-adds-AgriBusiness-1280x720.jpg

Renaissance BioScience Corp., a leader in bioengineering for the global agriculture and food industries, is pleased to announce that it has retained the services of S. Brad Griffith to assist Renaissance in commercializing its RNA production and oral delivery platform technology applications for agricultural crop protection, non-agriculture biocontrol and animal health. Mr. Griffith has more than 30 years’ experience in the agriculture industry and life sciences, much of it at a senior executive level, including leading the...

https://techpapersworld.com/wp-content/uploads/2022/11/eureKARE-co-leads-EUR-5-million-seed-investment-1280x720.jpg

eureKARE (“the Company”), an innovative investment company for disruptive synthetic biology applications, today announces that it has co-led a EUR 5 million seed funding round in Biomemory which is advancing cutting-edge DNA data synthesis and storage solutions. The round was led by eureKARE and the French Tech Seed Fund, managed by Bpifrance, with the support of Paris Business Angels, Prunay Impact and existing investors. Biomemory, founded in 2021, is positioned at the crossroads of Biotechnology...

https://techpapersworld.com/wp-content/uploads/2022/11/Top-Biopharmas-Elevate-1280x720.jpg

Veeva Systems (NYSE: VEEV) today announced three of the top ten biopharmas now use the recently released Veeva Link Scientific Awareness for real-time intelligence on product awareness and sentiment. Veeva Link Scientific Awareness delivers key success metrics across scientific, digital, and social channels to help medical teams optimize product strategy and effectively educate the scientific and medical community about different treatments. “Medical teams are shifting from volume-based activity metrics to value-driven standards that show the external impact of medical activities...

https://techpapersworld.com/wp-content/uploads/2022/11/WuXi-AppTec-Begins-Construction-of-Wuxi-STA-1280x720.jpg

WuXi AppTec recently held the groundbreaking ceremony for its Wuxi STA Pharmaceutical East China R&D facility in tandem with the signing ceremony for the Phase V CRDMO Project in Changzhou National High-Tech District. Jiangsu Governor Xu Kunlin delivered a speech celebrating the event via video, expressing his congratulations on the start of the project. He said that the Changzhou-based project of WuXi AppTec subsidiary Wuxi STA Pharmaceutical, with its view to creating an innovative pharmaceutical R&D and...

https://techpapersworld.com/wp-content/uploads/2022/11/FDA-Clears-the-Accure-Laser-1280x720.jpg

Accure Acne, Inc. (www.accureacne.com), a pioneer in the development of innovative solutions for the treatment of acne, announced today it has received FDA clearance for its Accure Laser™ System to treat mild to severe inflammatory acne vulgaris. The Accure Laser System builds upon the unique selectivity of the 1726nm laser wavelength, adding proprietary technology to precisely control thermal gradient depth.  This technology breakthrough is accomplished through a unique pulsing algorithm, integrated temperature monitoring, and precise...

https://techpapersworld.com/wp-content/uploads/2022/11/Novavax-Nuvaxovid-COVID-19-1280x720.jpg

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Health Canada has granted expanded authorization for Nuvaxovid™ (COVID-19 Vaccine (Recombinant protein, Adjuvanted)) (NVX-CoV2373) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a homologous booster in adults aged 18 and older. “Canadians now have access to our protein-based Nuvaxovid COVID-19 vaccine as an...

https://techpapersworld.com/wp-content/uploads/2022/11/Samyang-Holdings-Biopharmaceuticals-1280x720.jpg

Samyang Holdings Biopharmaceuticals Division’s lifting thread brand ‘Croquis,’ is actively targeting the Latin American market following the EU and expanding its market base. Samyang Holdings Biopharmaceuticals Division (CEO: Lee Young-Joon) announced on November 2nd that it held a webinar at the ‘IMCAS Academy’ to inform the safety and efficacy of Croquis and introduced the procedure. International Master Course on Aging Science (IMCAS) is one of the world’s three major medical aesthetics conferences, where the experts share the latest...

https://techpapersworld.com/wp-content/uploads/2022/11/ImaginAb-Executes-License-1280x720.jpg

ImaginAb Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent and radiopharmaceutical therapy (RPT) products, today announced the signing of a new multi-year, non-exclusive license agreement with DynamiCure Biotechnology, a private biopharmaceutical company developing innovative therapeutic antibody candidates to treat cancer, autoimmune disorders, and other diseases. Under the agreement, ImaginAb will license and supply clinical doses of its investigational CD8 ImmunoPET™ to DynamiCure Biotechnology for use in its clinical trial....

https://techpapersworld.com/wp-content/uploads/2022/11/Calliditas-partner-Everest-Medicines-1280x720.jpg

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the Chinese regulatory authority National Medical Products Administration (“NMPA”) has accepted Everest Medicines’ (HKEX 1952.HK, “Everest”) New Drug Application (“NDA”) for Nefecon. The acceptance brings Nefecon, approved and marketed in the U.S. under the name TARPEYO® and in the E.U. as Kinpeygo®, an important step closer to potentially becoming the first-ever approved therapeutic option indicated for primary IgAN treatment in China. In December 2020, the NMPA recommended Breakthrough Therapy Designation...